Study S003195

Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Overweight or Obesity, and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure (AMAZE 3)

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07571005
Acronym: AMAZE 3
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: RECRUITING
Enrollment: 300
Start: 2026-05-05
Primary completion: 2028-07-12
Lead sponsor: Novo Nordisk A/S
Conditions: Obesity; Overweight; Obstructive Sleep Apnoea
Interventions: DRUG:NNC0487-0111; DRUG:Placebo (matched to NNC0487-0111)
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1313-6359; OTHER:2024-520442-36

Registered primary outcomes

Relative change in body weight [From baseline (week 0) to (week 80)]
Change in apnoea-hypopnoea index (AHI) [From baseline (week 0) to (week 80)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.